Argos Therapeutics, Inc.

The Rockefeller University

Other

Friedrich-Alexander-Universitat Erlangen-Nürnberg

University of Antwerp

Universiteit Antwerpen

Schuler, Gerold

Merix Bioscience, Inc.

N.v. Antwerpes Innovatiecentrum

Gerold Schuler

Isolde Strobel

Viggo F.i. Van Tendeloo

Zwi N. Berneman

Peter Ponsaerts

Ralph M Steinman

Kayo Inaba

Detlef Dieckmann

Nina Bhardwaj

Isabell Pfeiffer

Katrin Birkholz

Jan Dörrie

Niels Schaft

Reinhard Voll

Beatrice Schuler-Thurner

Kalle Saksela

Andreas Baur

Zwi N Berneman

Viggo F I Van Tendeloo

Jan DÖRRIE

Viggo FI Van Tendeloo

Viggo Fi Van Tendeloo

The invention relates to dendritic cells, the NFκB signaling pathway of which has been manipulated by RNA transfection, to the manufacture thereof and to use thereof.

NF-B signaling pathway-manipulated dendritic cells

The invention relates to dendritic cells, the NF&#x3ba;B signaling pathway of which has been manipulated by RNA transfection, to the manufacture thereof and to use thereof.

NF-KB signaling pathway-manipulated dendritic cells

The present invention relates to a method for in vitro detection and/or monitoring of a disease in a sample, based on measurement of enzymatic activity of proteases activated and secreted upon disease development, to modified peptides used for the enzymatic detection of the proteases, the use of the peptides, a kit comprising such peptides and the use of ADAM-protease activity as a surrogate marker for disease burden and activity in infectious, inflammatory, and malignant diseases, such as HIV infection and melanoma.

Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles

The present invention provides suppressive and/or regulative human CD4CD25T cells, a method for expanding same, and the use of the suppressive and/or regulative human CD4CD25T cells and the expanded T cells as regulatory agent.

[object Object]

NF-&#x3ba;B signaling pathway-manipulated dendritic cells

The invention provides CD4CD25T cells and Tr1-like regulatory T cells (i.e., contact-independent Type 1-like regulatory T cells), processes for their production and their use for regulatory purposes.

The invention relates to a method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells especially for the production of a vaccine containing said dendritic cells, wherein immature dendritic cells are cultivated in the presence of suitable maturation stimuli and the mature dendritic cells thus obtained are frozen. The dendritic cells can be loaded with antigen before freezing. The invention also relates to a vaccine which can be obtained according to the inventive method and to a composition containing frozen, mature dendritic cells which are loaded with antigen.

Cryoconserved mature dendritic cells

Method for producing ready to use, antigen-loaded or unloaded, cryoconserved mature dendritic cells

CD4+CD25&#x2212; T cells and Tr1-like regulatory T cells

A method for producing proliferating cultures of dendritic cell precursors is provided. Also provided is a method for producing mature dendritic cells in culture from the proliferating dendritic cell precursors. The cultures of mature dendritic cells provide an effective means of producing novel T cell dependent antigens comprised of dendritic cell modified antigens or dendritic cells pulsed with antigen, including particulates, which antigen is processed and expressed on the antigen-activated dendritic cell. The novel antigens of the invention may be used as immunogens for vaccines or for the treatment of disease. These antigens may also be used to treat autoimmune diseases such as juvenile diabetes and multiple sclerosis.

Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens

We describe an improved method for generating sizable numbers of mature dendritic cells from nonproliferating progenitors in human blood. The first step or 'priming' phase is a culture of T cell depleted mononuclear cells in medium supplemented with GM-CSF and IL-4 to produce immature dendritic cells. The second step or 'differentiation' phase requires the exposure to dendritic cell maturation factor such as monocyte conditioned medium. Using this two-step approach, substantial yields are obtained. The dendritic cells derive from this method have all the features of mature cells. They include a stellate cell shape, nonadherence to plastic, and very strong T cell stimulatory activity. The mature dendritic cells produced according to this invention are useful for activating T cells.

Method and compositions for obtaining mature dendritic cells

The present invention provides an improved method for gene delivery in eukaryotic cells by electroporation, preferably in human hematopoietic cells, particular dendritic cells. The method of the invention is superior to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for gene delivery, including tumor antigen loading of dendritic cells.

Transfection of eukaryontic cells with linear polynucleotides by electroporation

Methods and compositions for obtaining mature dendritic cells

Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens for treating autoimmune diseases

Growing community of inventors

Spardorf, Germany

Gerold Schuler